AR127944A1 - Vacunas líquidas estabilizadas de virus vivos - Google Patents
Vacunas líquidas estabilizadas de virus vivosInfo
- Publication number
- AR127944A1 AR127944A1 ARP220103409A ARP220103409A AR127944A1 AR 127944 A1 AR127944 A1 AR 127944A1 AR P220103409 A ARP220103409 A AR P220103409A AR P220103409 A ARP220103409 A AR P220103409A AR 127944 A1 AR127944 A1 AR 127944A1
- Authority
- AR
- Argentina
- Prior art keywords
- vaccine
- stabilized liquid
- live viruses
- liquid vaccines
- live
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 6
- 239000007788 liquid Substances 0.000 title abstract 4
- 241000700605 Viruses Species 0.000 title abstract 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 2
- KIIBBJKLKFTNQO-WHFBIAKZSA-N 5-hydroxyectoine Chemical compound CC1=N[C@H](C(O)=O)[C@@H](O)CN1 KIIBBJKLKFTNQO-WHFBIAKZSA-N 0.000 abstract 1
- 241000004176 Alphacoronavirus Species 0.000 abstract 1
- WQXNXVUDBPYKBA-UHFFFAOYSA-N Ectoine Natural products CC1=NCCC(C(O)=O)N1 WQXNXVUDBPYKBA-UHFFFAOYSA-N 0.000 abstract 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract 1
- 239000000654 additive Substances 0.000 abstract 1
- 230000000996 additive effect Effects 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- WQXNXVUDBPYKBA-YFKPBYRVSA-N ectoine Chemical compound CC1=[NH+][C@H](C([O-])=O)CCN1 WQXNXVUDBPYKBA-YFKPBYRVSA-N 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000005496 eutectics Effects 0.000 abstract 1
- 229930182817 methionine Natural products 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14311—Parvovirus, e.g. minute virus of mice
- C12N2750/14334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
- C12N2760/18734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Reivindicación 1: Una composición de vacuna líquida que comprende un virus vivo y un portador farmacéuticamente aceptable, donde el portador es un disolvente natural eutéctico profundo (NADES) y la vacuna tiene una actividad de agua de como máximo 0,8, caracterizada porque la composición de vacuna líquida tiene una cantidad de agua de hasta un 50% p/p y la vacuna además comprende un aditivo seleccionado entre metionina, ectoína e hidroxiectoína. Reivindicación 6: La composición de vacuna líquida de acuerdo con la reivindicación 5, caracterizada porque el virus vivo envuelto se selecciona entre: un Paramixovirus y un Coronavirus.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21217481 | 2021-12-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR127944A1 true AR127944A1 (es) | 2024-03-13 |
Family
ID=79021629
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP220103409A AR127944A1 (es) | 2021-12-23 | 2022-12-13 | Vacunas líquidas estabilizadas de virus vivos |
Country Status (4)
Country | Link |
---|---|
AR (1) | AR127944A1 (es) |
AU (1) | AU2022422535A1 (es) |
CA (1) | CA3241031A1 (es) |
WO (1) | WO2023118426A1 (es) |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8247198B2 (en) | 2007-09-21 | 2012-08-21 | Friedrich Srienc | Enzymatic processing in deep eutectic solvents |
US8022014B2 (en) | 2008-03-26 | 2011-09-20 | Shrieve Chemical Products, Inc. | Deep eutectic solvents and applications |
JP5960120B2 (ja) | 2010-03-31 | 2016-08-02 | スタビリテック リミテッド | ウイルス粒子の安定化 |
NL2004835C2 (en) | 2010-06-07 | 2011-12-08 | Univ Leiden | Process for extracting materials from biological material. |
US9314519B2 (en) | 2012-08-21 | 2016-04-19 | Intervet Inc. | Liquid stable virus vaccines |
US9480739B2 (en) | 2013-03-15 | 2016-11-01 | Intervet Inc. | Bovine virus vaccines that are liquid stable |
US9393298B2 (en) | 2013-03-15 | 2016-07-19 | Intervet Inc. | Liquid stable bovine virus vaccines |
AR099470A1 (es) | 2014-02-17 | 2016-07-27 | Intervet Int Bv | Vacunas de virus de aves de corral líquidas |
AR113996A1 (es) | 2017-12-22 | 2020-07-08 | Intervet Int Bv | Vacunas líquidas de virus envueltos vivos |
AR118519A1 (es) | 2019-03-29 | 2021-10-20 | Intervet Int Bv | Estabilización de la bacteria mollicutes viva en una composición líquida |
-
2022
- 2022-12-13 AR ARP220103409A patent/AR127944A1/es unknown
- 2022-12-22 AU AU2022422535A patent/AU2022422535A1/en active Pending
- 2022-12-22 CA CA3241031A patent/CA3241031A1/en active Pending
- 2022-12-22 WO PCT/EP2022/087464 patent/WO2023118426A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
CA3241031A1 (en) | 2023-06-29 |
AU2022422535A1 (en) | 2024-06-13 |
WO2023118426A1 (en) | 2023-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201490802A1 (ru) | Препараты этанерцепта, стабилизированные меглюмином | |
CL2020001688A1 (es) | Vacunas liquidas de virus vivos envueltos. | |
PE20071243A1 (es) | Una composicion solida de taxano liofilizada, un procedimiento para preparar dicha composicion solida, una formulacion farmaceutica y un conjunto (kit) para la preparacion de una formulacion inyectable de taxano | |
UY37997A (es) | Agentes antivirales contra la hepatitis b | |
AR064561A1 (es) | Derivados de 2-aza-biciclo[3.1.0]hexano y su uso en la preparacion de un medicamento para el tratamiento de enfermedades relacionadas con disfunciones generales del sistema de la orexina. | |
ECSP066662A (es) | Preparación farmacéutica que comprende un anticuerpo contra el receptor egf | |
PE20070437A1 (es) | FORMULACION ACUOSA hFSH | |
DOP2013000172A (es) | Composicion farmaceutica | |
ECSP099780A (es) | Nuevos inhibidores macrociclicos de la replicacion del virus de hepatitis c | |
PE20080210A1 (es) | Suspensiones acuosas de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]-amino]-2-pirimidinil]-amino]-benzonitrilo (tmc278) | |
CR7140A (es) | Antranilamidas con una cadena colateral de un heteroarylsulfonil, metodos para la produccion de los mismos, su uso como medicamento o agente diagnostico y preparaciones farmaceuticas contenidas en dichos compuestos | |
BRPI0014869B8 (pt) | prostaglandinas bicíclicas, composições estabilizadas das mesmas, bem como processo para sua estabilização | |
EA201200096A1 (ru) | Фармацевтическая композиция ингибитора протеазы вируса гепатита c | |
AR038153A1 (es) | Formulaciones estabilizadas de adenovirus | |
AR050152A1 (es) | Dispersion con efecto insecticida y procedimiento para su preparacion | |
PE20220017A1 (es) | Inhibidores del kcnt1 y metodos de uso | |
AR110174A2 (es) | Agentes endoparasiticidas y procedimiento de preparación | |
PE20011223A1 (es) | Composicion farmaceutica que comprende pemetrexed y un antioxidante como monotioglicerol, l-cisteina y acido tioglicolico | |
MA43686B1 (fr) | Formulation liquide stable de gonadotrophines | |
AR127944A1 (es) | Vacunas líquidas estabilizadas de virus vivos | |
UY35390A (es) | Compuestos con actividad anti-hcv y composiciones farmacéuticas que los contienen | |
AR103719A1 (es) | Composición líquida tópica para el lavado intrauterino que contiene melatonina | |
PE20211454A1 (es) | Derivados de imidazopiridina y su uso como medicamento | |
CO2023000239A2 (es) | Excipientes reductores de viscosidad y combinaciones de los mismos para formulaciones de proteína altamente concentradas | |
AR029250A1 (es) | Derivados de milbemicina, composicion que los comprende y el uso de los mismos para la elaboracion de un medicamento contra insectos y otras plagas. |